GGrantIndex
← Leaderboards

Samuel Lai

Univ Of North Carolina Chapel Hill

Google Scholar ↗PubMed ↗ORCID ↗
$12,082,303
Attributed
$18,010,908
Total exposure
15
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.9M · FY2011–25
$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,010,908 · 15

By mechanism

R01$13,914,936 · 5
R21$2,258,598 · 6
U19$1,080,893 · 1
R41$449,891 · 2
R56$306,590 · 1

Top collaborators

Most similar at Univ Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Antibodies”

Research focus

AntibodiesDoseAffinityCellsImmunoglobulin GIn VivoMucous Body SubstanceEngineeringMonoclonal AntibodiesLeadInfectionVaginaDesignBaseImmunePreventResearch PersonnelBloodSafetyCrosslinkBindingSurfaceVirusIn Vitro

Grant awards (39)

ACE2 immunodecoys for long-lasting immunoprophylaxis against sarbecovirus and merbecoviruses that target human ACE2$2,937,578
R01 · FY2025 · AI · contact PI
Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections$535,133
R01 · FY2025 · AI · contact PI
Engineering non-replicating self-recirculating phages as platform for gene therapy of the microbiome$233,250
R21 · FY2025 · AI · contact PI
In vivo engineering of chimeric antibody reprogrammed (CAR) B cells with fully tunable antibody response$188,544
R21 · FY2025 · AI · contact PI
Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception$728,629
R01 · FY2024 · HD
Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections$629,240
R01 · FY2024 · AI · contact PI
In vivo engineering of chimeric antibody reprogrammed (CAR) B cells with fully tunable antibody response$233,250
R21 · FY2024 · AI · contact PI
Engineering Siglec15/TGF-beta targeted bispecific antibodies that modulate the tumor microenvironment and enhances T-cell immunotherapy against pancreatic cancer$169,563
R21 · FY2024 · CA · contact PI
Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception$746,693
R01 · FY2023 · HD
Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections$688,330
R01 · FY2023 · AI · contact PI
Engineering bispecific antibodies for non-hormonal contraception$493,843
R01 · FY2023 · HD · contact PI
Engineering Siglec15/TGF-beta targeted bispecific antibodies that modulate the tumor microenvironment and enhances T-cell immunotherapy against pancreatic cancer$214,931
R21 · FY2023 · CA · contact PI
Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception$740,660
R01 · FY2022 · HD
Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections$688,413
R01 · FY2022 · AI · contact PI
Engineering bispecific antibodies for non-hormonal contraception$519,965
R01 · FY2022 · HD · contact PI
Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception$744,855
R01 · FY2021 · HD
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics$674,568
R01 · FY2021 · HL · contact PI
Engineering bispecific antibodies for non-hormonal contraception$520,731
R01 · FY2021 · HD · contact PI
Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception$759,199
R01 · FY2020 · HD
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics$685,484
R01 · FY2020 · HL · contact PI
Engineering bispecific antibodies for non-hormonal contraception$523,187
R01 · FY2020 · HD · contact PI
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics$664,881
R01 · FY2019 · HL · contact PI
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics$633,547
R01 · FY2018 · HL · contact PI
An integrated neural network analysis and video microscopy platform for fully automated particle tracking$224,894
R41 · FY2018 · GM · contact PI
Development of novel sperm-binding antibodies$306,590
R56 · FY2017 · HD · contact PI
Artificial neural networks for high performance, fully automated particle tracking analysis even at low signal-to-noise regimes$224,997
R41 · FY2017 · GM · contact PI
Prevalence and characteristics of anti-PEG antibodies in humans$224,429
R21 · FY2015 · EB · contact PI
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus$159,258
U19 · FY2015 · AI · contact PI
Prevalence and characteristics of anti-PEG antibodies in humans$188,267
R21 · FY2014 · EB · contact PI
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus$181,281
U19 · FY2014 · AI · contact PI
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus$27,182
U19 · FY2014 · AI · contact PI
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus$196,429
U19 · FY2013 · AI · contact PI
Diffusion of viruses across human airway mucus and trapping by antibodies$219,709
R21 · FY2012 · AI · contact PI
Trapping HIV in mucus with IgG antibodies$219,709
R21 · FY2012 · AI · contact PI
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus$190,446
U19 · FY2012 · AI · contact PI
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus$26,134
U19 · FY2012 · AI · contact PI
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus$300,163
U19 · FY2011 · AI · contact PI
Diffusion of viruses across human airway mucus and trapping by antibodies$183,473
R21 · FY2011 · AI · contact PI
Trapping HIV in mucus with IgG antibodies$183,473
R21 · FY2011 · AI · contact PI